vorinostat has been researched along with Muscular Dystrophy, Duchenne in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The following parameters were evaluated: (i) number of ventricular arrhythmias in resting and stress conditions (restraint test) or after aconitine administration; (ii) cardiac excitability, conduction velocity, and refractoriness; (iii) expression and distribution of connexins (Cxs) and Na(v)1." | 3.76 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. ( Baruffi, S; Berni, R; Bocchi, L; Capogrossi, MC; Colussi, C; Delucchi, F; Gaetano, C; Macchi, E; Mai, A; Musso, E; Quaini, F; Rosati, J; Rossi, S; Rotili, D; Savi, M; Spallotta, F; Stilli, D; Straino, S; Vitale, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colussi, C | 3 |
| Berni, R | 2 |
| Rosati, J | 2 |
| Straino, S | 3 |
| Vitale, S | 1 |
| Spallotta, F | 3 |
| Baruffi, S | 1 |
| Bocchi, L | 1 |
| Delucchi, F | 1 |
| Rossi, S | 2 |
| Savi, M | 1 |
| Rotili, D | 2 |
| Quaini, F | 1 |
| Macchi, E | 2 |
| Stilli, D | 2 |
| Musso, E | 2 |
| Mai, A | 3 |
| Gaetano, C | 3 |
| Capogrossi, MC | 3 |
| Banfi, C | 1 |
| Brioschi, M | 1 |
| Tremoli, E | 1 |
| Sbardella, G | 1 |
| Castellano, S | 1 |
| Chimenti, C | 1 |
| Frustaci, A | 1 |
| Nebbioso, A | 1 |
| Altucci, L | 1 |
3 other studies available for vorinostat and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
Topics: Aconitine; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexins; Dise | 2010 |
Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.
Topics: Amino Acid Sequence; Animals; Blood Proteins; Dose-Response Relationship, Drug; Gene Expression Regu | 2010 |
Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart.
Topics: Acetylation; Anacardic Acids; Animals; Cardiomyopathies; Connexin 43; Gap Junctions; Histone Acetylt | 2011 |